Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

NCT03711305 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

462

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

DRUG: SHR-1316
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.